Oncopeptides
4 SEK -11.89%1 investor is following this company
Oncopeptides is a biotech company that develops drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic drugs into cancer cells. The company has begun the commercialization of its first drug and has several drug candidates under development. Oncopeptide's head office is located in Stockholm.
Revenue
35.22M
EBIT %
-719.62 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ONCO
Daily low / high price
3.83 / 4.38
SEK
Market cap
860.74M SEK
Turnover
6.21M SEK
Volume
1.5M
Latest videos
Financial calendar
General meeting
2024-05-22
Interim report
2024-05-30
Interim report
2024-08-14
Interim report
2024-11-07
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
HealthCap VI L.P | 17.3 % | 18.1 % |
Stiftelsen Industrifonden | 8.8 % | 9.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Oncopeptides publishes prospectus relating to the rights issue
Oncopeptides offentliggör prospekt avseende företrädesemissionen
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools